openPR Logo
Press release

Chronic Hepatitis C In 12 Major Markets includes Gilead, Johnson & Johnson, Bristol-Myers Squibb Company, Merck & Co., Inc., AbbVie Inc. & Biocon

10-05-2018 08:05 AM CET | Health & Medicine

Press release from: Research Cosmos

Chronic Hepatitis C In 12 Major Markets includes Gilead, Johnson

Chronic Hepatitis C In 12 Major Markets Overview:
Hepatitis is defined as inflammation of the liver due to infection with a virus or other causative organism or toxin. Hepatitis C, on the other hand, results mainly from infection with the hepatitis C virus (HCV). With a cure rate of 50% to 80% and no commercially available vaccine, hepatitis C is considered a life-threatening disease with a moderate to high infection rate. It is the main cause of liver transplantation in the United Kingdom and North America.

The transmission of this virus in most cases comes from the abuse of injectable drugs, the virus can only be transmitted by contact with blood. Secondary transmission factors include tattoos, sexual contact, blood transfusion, organ transplantation and other rare cases. The diagnosis of hepatitis C is also very delicate because there is a risk of misdiagnosis because it is possible that the virus is not detected in a liver biopsy sample. Liver enzyme levels may remain normal for an infected person for years. In some cases, an infected person can reach 30 years without showing symptoms of infection. PCR amplification of purified and centrifuged biopsy samples at specific time intervals is the best-proven method for near precision diagnosis.

Browse report brief and TOC @ https://www.researchcosmos.com/reports/chronic-hepatitis-c-in-12-major-markets-forecast-report-2017-2027/1499812566

Chronic Hepatitis C In 12 Major Markets Drivers and Restraints:
Currently, the market cost of antivirals and interferon remains the biggest barrier to the proliferation of the therapeutic market for hepatitis C. Prices range from a few hundred dollars to thousands of dollars for a single dose. In general, insurance companies do not cover the total cost of drugs in the standard coverages often, and only first-rate people can afford the treatment. Immunization research in progress can also be an obstacle in the future because preventive vaccination has always been more successful than therapeutic vaccines. The therapeutic market for hepatitis C continues to be in the billions, with new combinations patented each year with its own market segment. They are currently one of the most coveted investment segments in the healthcare sector. With the entry of Asian players, prices should also fall, which could increase the therapeutic market.

Request free sample @ https://www.researchcosmos.com/request/chronic-hepatitis-c-in-12-major-markets-forecast-report-20/1499812566

Geographic Segmentation:
The North American market is the highest market by volume, followed by Europe, as in these regions reported cases are high in number, and so is the affordability of drugs. The major cause for Hepatitis C transmission in developed nations is intravenous narcotic/psychedelic drug abuse, which is common in these regions. In developing markets of Asia and South America, the leading cause for transmission is healthcare exposure and their poor standards. This along with their population size make a large market, however, unavailability of affordable drugs is often the reason why the markets haven’t been proliferated yet. However the recent growth of market in Asia Pacific is a positive sign for potential manufacturers. The rest of the world also follows a similar pattern.

Inquire Before Buying @ https://www.researchcosmos.com/inquire/chronic-hepatitis-c-in-12-major-markets-forecast-report-20/1499812566

Key Players In Chronic Hepatitis C In 12 Major Markets:
Key players active in the Hepatitis C Therapeutics Market includes Gilead, Johnson & Johnson, Bristol-Myers Squibb Company, Merck & Co., Inc., AbbVie Inc. & Biocon.

About Us:
Research Cosmos is a provider of standard and customized market research, business intelligence and consulting services across more than 100 domains in different industries of the world. We host the trending market reports of the world’s top-notch publishing companies, offering services to a wide range of customers from students to fortune 500 companies and discloses the hidden opportunities in every leading industry of the world.  

Contact: 
Kevin Stewart
kevin@researchcosmos.com
Global Sales Manager
Research Cosmos
www.researchcosmos.com
+1 888 709 8757   
LinkedIn - https://www.linkedin.com/company/market-research-cosmos
Twitter - https://twitter.com/researchcosmos
Google+ -  https://plus.google.com/109756852849129986268
Facebook - https://www.facebook.com/researchcosmos/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Chronic Hepatitis C In 12 Major Markets includes Gilead, Johnson & Johnson, Bristol-Myers Squibb Company, Merck & Co., Inc., AbbVie Inc. & Biocon here

News-ID: 1282190 • Views:

More Releases from Research Cosmos

Mobile Phone Insurance Market Size to Reach USD 32.24 Bn By 2025
Mobile Phone Insurance Market Size to Reach USD 32.24 Bn By 2025
The size of the Global mobile phone insurance market is estimated to reach USD 32.24 billion by 2025, growing at a CAGR of 12.5%, as per the recently published report by Research Cosmos. It is worth to claim insurance for mobile phones as we are spending a lot of money on purchasing. The policies include accidental damage, water damage, and screen cracking. Browse details of the report @ https://www.researchcosmos.com/reports/mobile-phone-insurance-market/199557834 Growing utilization
Social Employee Recognition Systems Market Predicted to grow at a CAGR of xx By 2025 | Leading Market Players - Kudos, Achievers Corp., REFFIND Ltd., Globoforce, Terryberry, Ultimate Software, Peoplecart, CorporateRewards
Social Employee Recognition Systems Market Predicted to grow at a CAGR of xx By …
Social Employee Recognition Systems Market Analysis Size, Growth rate and Overview: Social Employee Recognition Systems Market was valued at USD xx million in 2018 and is expected to reach almost USD xx million by the end of 2025, growing at a CAGR of around xx% over the predicted period. Throughout the world, social employee recognition systems have expanded dramatically to address the need to move away from traditional methods and programs of

More Releases for Hepatitis

Is Hepatitis A Vaccine Required?
Hepatitis A Vaccine Market describes its growth, size, share, Forecast and trends to 2025 Hepatitis A vaccine is a vaccine which is against the hepatitis A virus. The Hepatitis A vaccine is available for long-term prevention of HAV infection, Minimum age for HAV vaccination is 1 year. Two types of HAV vaccines are currently available internationally: 1. Formaldehyde-inactivated vaccines: Inactivated HAV vaccines are used in most countries. Monovalent inactivated HAV vaccines are available
Hepatitis Drugs Market Is Growing Due to Increasing R&D Investments on Hepatitis …
The global hepatitis drugs market is growing due to increasing incidences of hepatitis and increasing support from government organizations. In addition, the growing geriatric population, and increasing R&D investments on hepatitis research and drug discovery are also driving the growth of the global hepatitis drugs market. Access Detailed Report Summary: https://www.psmarketresearch.com/market-analysis/hepatitis-drugs-market Among the various types, the hepatitis C segment is expected to be the largest segment, and expected to witness the fastest
Hepatitis B Therapeutics Market Is Driven by Rising Incidence of Hepatitis B In …
Hepatitis B is a life threatening liver infection caused by hepatitis B virus. Adults who get affected by hepatitis B virus for a short time and then get cured is known as acute hepatitis B. Infection that lasts for a long time is known as chronic hepatitis B. Vaccine is the most preferred choice of doctors and physicians to protect people from the disease. The vaccine prevents the infection and
Hepatitis E Hyperendemicity to Drive Hepatitis E Diagnostic Tests Market Growth
Global Hepatitis E Diagnostic Tests Market: Snapshot The growing incidence of hepatitis E, a liver disease caused by infection due to the virus hepatitis E virus (HEV), is a leading cause of morbidity and mortality worldwide. There is increasing prevalence of hepatitis E in resource-limited region, such as various countries of Asia Pacific. The people of these regions suffer with frequent water contamination and have limited access to sanitation and hygiene,
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Hepatitis C Drug Pipeline Analysis
“Hepatitis C Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles being developed for the treatment of Hepatitis C. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. Insight for each